We are live on ! Find out more
CTNM

Contineum Therapeutics
CTNM

80 hedge funds and large institutions have $338M invested in Contineum Therapeutics in 2025 Q4 according to their latest regulatory filings, with 31 funds opening new positions, 29 increasing their positions, 8 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

263% more repeat investments, than reductions

Existing positions increased: 29 | Existing positions reduced: 8

182% more first-time investments, than exits

New positions opened: 31 | Existing positions closed: 11

64% more capital invested

Capital invested by funds: $206M → $338M (+$133M)

47.2% more ownership

Funds ownership: 80.95% → 128.15% (+47%)

29% more funds holding

Funds holding: 62 → 80 (+18)

0% more funds holding in top 10

Funds holding in top 10: 4 → 4 (0)

27% less call options, than puts

Call options by funds: $117K | Put options by funds: $160K

Holders
80
Holders Change
+18
Holders Change %
+29.03%
% of All Funds
0.97%
Holding in Top 10
4
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.05%
New
31
Increased
29
Reduced
8
Closed
11
Calls
$117K
Puts
$160K
Net Calls
-$43K
Net Calls Change
-$273K

Top Buyers

Rank Fund Capital Flow
1
Janus Henderson Group
Janus Henderson Group
United Kingdom
+$27.9M
2
BBA
Baker Bros. Advisors
New York
+$15.3M
3
SCM
Suvretta Capital Management
New York
+$12.8M
4
Balyasny Asset Management
Balyasny Asset Management
Illinois
+$10.2M
5
CC
Commodore Capital
New York
+$9.31M

Top Sellers

Rank Fund Capital Flow
1
SB
Samsara BioCapital
California
-$5.69M
2
BEAM
Baker Ellis Asset Management
Washington
-$229K
3
RC
RBF Capital
California
-$228K
4
Squarepoint
Squarepoint
New York
-$154K
5
B
Bailard
California
-$145K
Name Holding Trade Value Shares
Change 		Change in
Stake
Geode Capital Management
26
Geode Capital Management
Massachusetts
$2.45M +$32.2K +2,819 +1%
Ameriprise
27
Ameriprise
Minnesota
$2.4M +$2.39M +209,633 New
UBS Group
28
UBS Group
Switzerland
$2.28M +$1.49M +130,885 +191%
Marshall Wace
29
Marshall Wace
United Kingdom
$2.07M -$145K -12,687 -7%
SFM
30
Sphera Funds Management
Israel
$1.98M +$1.98M +173,475 New
CC
31
Casdin Capital
New York
$1.7M – – –
EP
32
Eversept Partners
New York
$1.57M +$32.8K +2,874 +2%
MIM
33
Monashee Investment Management
Massachusetts
$1.57M +$1.57M +137,430 New
Morgan Stanley
34
Morgan Stanley
New York
$1.42M +$357K +31,291 +34%
Charles Schwab
35
Charles Schwab
California
$1.26M -$1.33K -117 -0.1%
Goldman Sachs
36
Goldman Sachs
New York
$1.21M +$861K +75,459 +250%
6CM
37
683 Capital Management
New York
$1.05M +$1.04M +91,442 New
State Street
38
State Street
Massachusetts
$965K +$251K +22,000 +35%
BFM
39
Boothbay Fund Management
New York
$829K +$827K +72,494 New
SB
40
Samsara BioCapital
California
$826K -$5.69M -498,897 -87%
Acadian Asset Management
41
Acadian Asset Management
Massachusetts
$735K +$436K +38,235 +144%
BNP Paribas Financial Markets
42
BNP Paribas Financial Markets
France
$734K +$730K +64,008 +29,095%
Barclays
43
Barclays
United Kingdom
$680K +$605K +53,031 +819%
TI
44
Trexquant Investment
Connecticut
$675K +$339K +29,721 +101%
Renaissance Technologies
45
Renaissance Technologies
New York
$653K +$181K +15,900 +39%
Northern Trust
46
Northern Trust
Illinois
$616K +$56.1K +4,913 +10%
ECM
47
ExodusPoint Capital Management
New York
$583K +$582K +51,028 New
SWA
48
Strategies Wealth Advisors
Michigan
$572K – – –
BCM
49
Bridgeway Capital Management
Texas
$563K +$87.9K +7,700 +19%
Qube Research & Technologies (QRT)
50
Qube Research & Technologies (QRT)
United Kingdom
$492K +$491K +43,078 New
1
2
3 4

CTNM Hedge Fund Activity: Q4 2025 in Review

80 of the 8,223 institutional investors tracked by Wall St. Rank reported a position in Contineum Therapeutics (CTNM) for Q4 2025, worth a combined $338M — up 64% from $206M a quarter earlier.

Buyers outnumbered sellers: 31 funds opened new CTNM positions and 11 closed out — a net gain of 20 holders — while 29 added to existing stakes and 8 trimmed.

The largest buyer was Janus Henderson Group, opening a new position worth an estimated $27.9M. The largest seller was Samsara BioCapital, cutting an estimated $5.69M.

  • 80 institutional investors held Contineum Therapeutics (CTNM) as of Q4 2025, up from 62 in Q3 2025.
  • Funds reported $338M of Contineum Therapeutics stock for Q4 2025, up 64% quarter-over-quarter.
  • 31 funds opened new Contineum Therapeutics positions in Q4 2025 and 11 closed out, a net change of +20 holders.
  • The largest Contineum Therapeutics buyer in Q4 2025 was Janus Henderson Group, an estimated $27.9M added.
  • The largest Contineum Therapeutics seller in Q4 2025 was Samsara BioCapital, an estimated $5.69M sold.

Based on aggregated 13F filings for Q4 2025.